Taken together, the relatively high HER2 amplification rate in cervical GAC, which was comparable to that reported in gastric cancers (12.2–20%) [14, 29, 34], may suggest the particular treatment implications for these patients on account of their poor clinical outcomes. The gene discussed is ERBB2; the disease is gastric cancer.